Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

This study investigated patients with primary lung cancer who received PET/CT scan, a medical imaging test, and subsequently ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Immunotherapy has dramatically improved the treatment outcomes of primary lung cancer; however, it sometimes causes a serious ...

Addition of the immunotherapy drug pembrolizumab to standard of care ... Duke University and Princess Margaret Cancer Centre, University Health Network. The findings, published today in The Lancet, ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target ...

Researchers think they’ve figured out why cancer treatments that harness a person’s immune system to fight a tumor can ...